Eli Lilly soars 5% after positive Alzheimer’s trial

Shares of Eli Lilly And Co. jumped over 5% on Wednesday after the company released the result of the phase 3 study of Alzheimer’s disease medicine donanemab. The trial included 1,736 participants …